Saturday 17 October 2026 Export ENOV’s income statement to Excel — free account

Enovis Corporation

Enovis Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 6.66% from fiscal 2024. In the quarter to June 2026, revenue grew 3.23%, EPS grew 96.9%, free cash flow grew 815.8% and total debt fell 7.82%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

19.59 0.24 +1.24%

Follow ENOV

Alert me

Market cap: $1.1B
P/E: 0.0×
Fwd P/E: 195×
Dividend yield: —
F-score: 4/9
Altman Z: −0.34
Beneish M: −4.29
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.76

Total sells 0.05

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	1	—	—	1	4	—	—	4	—	—	3	—
Sell	—	1	—	—	—	—	—	—	—	—	—	—

Insider Ownership 2.36%

Capital & Financial Ratios $m

Market Cap 1,120.00

Revenue 2,296.60

Net Income (1,100.85)

Free Cash Flow 63.66

Net Debt 1,271.95

Current Ratio 1.98

Debt/Equity 0.87

P/E ratio 0.00

Fwd P/E 195.00

P/S ratio 0.49

P/B ratio 0.76

Past 5Y EPS Growth —

This Y EPS Growth 9.91%

Next Y EPS Growth (2.31%)

Next Y revenue growth 4.05%

Next 5Y EPS Growth 6.00%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 2.58%

10-year low 10-year high

P/B against its own 10 years 43.24%

10-year low 10-year high

EV/Sales against its own 10 years 8.51%

10-year low 10-year high

EV/FCF against its own 10 years 66.63%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2026	Powerpack
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	36	48	36	13
Receivables	291	407	443	442
Inventory	469	547	584	602
Other	71	108	101	110
	897	1,146	1,207	1,215

	2023	2024	2025	Q'26
Payables	132	179	188	194
ST’ Debt	—	20	35	37
Other	—	—	—	—
	370	529	598	612

Compound Annual Growth %

	10y	5y	3y
Sales	(4.15%)	14.94%	12.88%
Cash Flow	(3.30%)	(6.37%)	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(7.51%)	(16.10%)	(24.38%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	589	583	—	—	—
’25	559	565	549	576	2,248
’24	516	525	505	561	2,108
’23	406	429	418	455	1,707
’22	375	395	384	409	1,563
’21	879	356	360	(169)	1,426
’20	816	620	806	(1,122)	1,121

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	24	75	—	—	—
’25	(2)	48	83	89	217
’24	(36)	8	54	88	114
’23	7	28	31	68	135
’22	(14)	(25)	19	(36)	(56)
’21	84	78	97	96	356
’20	56	37	80	129	302

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(29)	31	—	—	—
’25	(45)	3	29	32	20
’24	(73)	(32)	2	35	(67)
’23	(23)	(9)	47	30	45
’22	(36)	(49)	(1)	(73)	(159)
’21	60	61	68	70	259
’20	27	21	49	100	197

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.15)	(0.02)	—	—	—
’25	(0.98)	(0.64)	(9.99)	(9.10)	(20.75)
’24	(1.32)	(0.34)	(0.58)	(12.05)	(14.93)
’23	(0.43)	(0.18)	(0.05)	0.05	(0.61)
’22	0.33	1.41	(1.23)	(0.71)	(0.25)
’21	0.39	0.54	0.48	(0.03)	1.38
’20	0.09	(0.18)	0.30	0.72	0.93

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	31.36	57.33	32.62	34.44	21.05	62.98	43.88	43.04	38.27	25.47	Analyst estimates 2026–2028 Powerpack
	High	68.57	74.51	72.43	63.30	67.64	94.10	81.94	66.71	65.03	49.38
People
People	Employees	13,000	14,300	15,500	15,000	15,400	16,200	6,800	6,550	7,367	7,802
	Revenue/emp, $m	0.25	0.14	0.14	0.22	0.07	0.09	0.23	0.26	0.29	0.29
Income, $m
Income, $m	Revenue	3,186	1,937	2,193	3,327	1,121	1,426	1,563	1,707	2,108	2,248
	Gross margin, %	31.15	34.67	33.26	42.11	53.86	54.53	55.62	58.04	56.02	59.84
	EBT	207	49	92	50	(119)	(122)	(2)	(67)	(823)	(1,159)
	EBT margin, %	6.48	2.51	4.21	1.52	(10.62)	(8.54)	(0.13)	(3.93)	(39.05)	(51.57)
	Net income	145	170	154	(517)	46	76	(12)	(33)	(825)	(1,184)
	Depreciation	143	316	149	236	246	263	220	217	935	1,344
Per share, $
Per share, $	Revenue	77.76	47.17	54.70	73.56	24.58	27.89	28.91	31.33	38.13	39.39
	Earnings	3.12	3.69	3.48	(11.67)	0.93	1.41	(0.25)	(0.61)	(14.93)	(20.75)
	Cash flow	6.03	5.33	5.65	2.89	6.62	6.96	(1.03)	2.48	2.05	3.81
	Capex	(1.37)	(1.16)	(0.87)	(2.60)	(2.31)	(1.90)	(1.90)	(1.65)	(3.27)	(3.46)
	Free cash flow	4.66	4.17	4.78	0.29	4.31	5.06	(2.93)	0.83	(1.22)	0.35
	Book value	75.51	90.75	86.72	77.15	78.70	91.15	63.81	62.77	46.39	26.14
	Shares, m	41	41	40	45	46	51	54	54	55	57
Valuation, ×
Valuation, ×	P/E	20.35	18.73	10.25	0.00	70.77	54.94	0.00	0.00	0.00	0.00
	P/S	0.82	1.45	0.66	0.85	2.68	2.84	1.88	1.77	1.15	0.68
	P/B	0.84	0.76	0.41	0.81	0.84	0.87	0.85	0.88	0.95	1.02
	EV/Sales	1.16	1.79	1.17	1.51	4.58	3.82	2.03	2.03	1.76	1.24
	EV/FCF	19.30	20.23	13.38	377.79	26.10	21.06	(20.03)	76.59	(55.16)	139.62
Cash, $m
Cash, $m	Operating cash flow	247	219	226	131	302	356	(56)	135	114	217
	Capex	(56)	(48)	(35)	(118)	(105)	(97)	(103)	(90)	(181)	(197)
	Free cash flow	191	171	192	13	197	259	(159)	45	(67)	20
Balance, $m
Balance, $m	Working capital	679	972	759	547	550	1,280	230	527	617	609
	Total debt	1,292	1,061	1,197	2,312	2,231	2,086	259	466	1,330	1,297
	Net debt	1,083	649	1,120	2,202	2,134	1,406	235	430	1,281	1,260
	Shareholders’ equity	3,093	3,727	3,477	3,490	3,588	4,661	3,450	3,421	2,564	1,492
Returns, %
Returns, %	ROA	1.96	2.32	2.10	(7.54)	0.58	0.90	(0.21)	(0.76)	(17.89)	(27.69)
	ROIC	3.54	1.94	2.06	2.24	(0.72)	(0.65)	(1.21)	(1.07)	(12.61)	(25.53)
	ROE	4.04	4.43	3.89	(15.15)	1.20	1.74	(0.33)	(0.97)	(27.59)	(58.40)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
BVS Bioventus Inc.	$1.2B	16.4×	21.4×	+3.76% (above 0%: growing)	+345.45% (above 0%: growing)	−25.11% (below 0%: shrinking)	68.97%	12.48%	Compare
TNDM Tandem Diabetes Care, Inc.	$1.2B	— (loss-making)	— (loss-making)	+5.77% (above 0%: growing)	n/m	−146.34% (below 0%: shrinking)	56.87%	(5.42%)	Compare
IRMD iRadimed Corporation	$1.1B	48.5×	48.7×	+0.28% (above 0%: growing)	−8.89% (below 0%: shrinking)	+11.66% (above 0%: growing)	74.07%	31.23%	Compare
ENOV Enovis Corporation	$1.1B	— (loss-making)	195×	+3.23% (above 0%: growing)	n/m	+815.79% (above 0%: growing)	61.64%	2.99%
AORT Artivion, Inc.	$1.1B	— (loss-making)	142×	+11.32% (above 0%: growing)	n/m	−202.47% (below 0%: shrinking)	64.03%	(6.65%)	Compare
CBLL CeriBell, Inc.	$1.1B	— (loss-making)	— (loss-making)	+32.54% (above 0%: growing)	n/m	−68.63% (below 0%: shrinking)	92.32%	(71.11%)	Compare
IART Integra LifeSciences Holdings Corporation	$1.1B	— (loss-making)	26.1×	+0.76% (above 0%: growing)	n/m	+193.48% (above 0%: growing)	52.47%	4.61%	Compare
LMRI Lumexa Imaging Holdings, Inc.	$1.0B	— (loss-making)	14.2×	+7.82% (above 0%: growing)	n/m	+257.54% (above 0%: growing)	14.72%	8.72%	Compare
PRCT PROCEPT BioRobotics Corporation	$1.0B	— (loss-making)	— (loss-making)	+19.34% (above 0%: growing)	n/m	−24.43% (below 0%: shrinking)	66.01%	(28.98%)	Compare
Median of peers	$1.1B	—	26.1×	+6.80%	—	−24.77%	65.02%	(0.40%)

All 149 Medical Devices stocks →

Enovis Corporation (ENOV) key facts

Strength: Enovis Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 6.66% from fiscal 2024.
Enovis Corporation (ENOV) is a Medical Devices company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 16, 2026, ENOV traded at $19.59, a market capitalization of $1.1 billion.
Return on equity was −58.4% and debt-to-equity 0.87.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −0.34 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.